With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...

The National Medical Products Administration in China has approved two Sanofi (SNY) medicines for rare hematologic diseases: Qfitlia for ...

Investing.com -- Sanofi has received approval for two bleeding disorder treatments in China, expanding its hematology portfolio in the country. The French pharmaceutical company announced Thursday ...

Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...

Sanofi said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the country. The French pharmaceutical company ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

DelveInsight's Hemophilia A Market Insights report includes a comprehensive understanding of current treatment practices, hemophilia A emerging drugs, market share of individual therapies, and current ...